Propanc Biopharma, Inc.

Latest News

Mar 16, 2023

Propanc Biopharma Confirms PRP Exerts Significant Effects Against Chemoresistant Pancreatic Tumor Cells

MELBOURNE, Australia--(BUSINESS WIRE)-- Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from…

View All Press Releases

Jan 11, 2023

Propanc Biopharma’s Joint Researcher Presents at the 43rd Meeting of the European Organization of Research & Treatment of Cancer (EORTC)

Dec 15, 2022

Propanc Biopharma’s Joint Researcher Receives Award at Doctoral Conference at the University of Jaén

Nov 30, 2022

Propanc Biopharma Concludes PRP Could Become an Effective Chemosensitizer Agent Against Pancreatic Cancer
Latest Publication Blocking Tumor Support from Cancer-Associated Fibroblasts in Tumor Microenvironment View All Publications
Trypsinogen and chymotrypsinogen: potent anti- tumor agents
Pancreatic (pro)enzymes treatment suppresses BXPC-3 pancreatic Cancer Stem Cell subpopulation and impairs tumour engrafting
Antitumour efficacy of chymotrypsinogen and trypsinogen